We first identified monogenic risk variants by sequencing the BRCA1 and BRCA2 genes in 1920 breast cancer cases and 17,344 controls, all female, from the Color Genomics commercial testing laboratory (Table 2)20. This evidence concerns the gene BRCA2 and breast carcinoma.